FIELD: biotechnology.
SUBSTANCE: present invention relates to novel peptides of botulinum neurotoxin (BoNT) and can be used in medicine and cosmetology. Invention discloses a chimeric heavy chain binding domain (HC/TAB) of BoNT, which has been adapted to provide synergistic binding of the SV2C receptor, synaptotagmin receptor and ganglioside receptor, and also has improved duration of action and effectiveness in comparison with native analogue.
EFFECT: invention can be used in designing polypeptides and other hybrid molecules for the purpose of their subsequent use as a local muscle relaxant in the therapy of diseases associated with undesirable activity of neurons, as well as caused by muscle hypertonicity or spasms.
32 cl, 17 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ENGINEERED BOTULINUM NEUROTOXIN | 2016 |
|
RU2746736C2 |
| CONSTRUCTED BOTULINUM NEUROTOXIN | 2017 |
|
RU2789302C2 |
| HYBRID NEUROTOXINS | 2017 |
|
RU2782382C2 |
| THERAPEUTIC AND COSMETIC USE OF SEROTYPE E NEUROTOXIN BOTULINUM | 2019 |
|
RU2800604C2 |
| TRISPECIFIC BINDING MOLECULES FOR TREATING VIRAL HEPATITIS B INFECTION AND BOUND STATES | 2016 |
|
RU2733496C2 |
| METHODS FOR PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDES | 2018 |
|
RU2719164C1 |
| MUTANT VARIANTS OF Fc IgG1 DEVOID OF EFFECTOR FUNCTIONS | 2018 |
|
RU2764559C2 |
| ANTIBODIES BINDING TO HUMAN CANNABINOID RECEPTOR 1 (CB1) | 2015 |
|
RU2730674C2 |
| ANTI-SIRPα ANTIBODIES | 2018 |
|
RU2771174C2 |
| HUMAN ANTIBODIES BINDING TO ROR2 | 2018 |
|
RU2784586C2 |
